Cargando…

Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies

BACKGROUND: Inflammatory myopathies (IMs) are a group of rare conditions characterized by proximal and often symmetrical muscle weakness and reduced muscle endurance. The recommended medical treatment is based on corticosteroids in combination with immunosuppressants. This anti-inflammatory therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfister, Pierrette Baschung, Knols, Ruud H., de Bie, Rob A., de Bruin, Eling D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157458/
https://www.ncbi.nlm.nih.gov/pubmed/34039438
http://dx.doi.org/10.1186/s40945-021-00108-z
_version_ 1783699687998488576
author Pfister, Pierrette Baschung
Knols, Ruud H.
de Bie, Rob A.
de Bruin, Eling D.
author_facet Pfister, Pierrette Baschung
Knols, Ruud H.
de Bie, Rob A.
de Bruin, Eling D.
author_sort Pfister, Pierrette Baschung
collection PubMed
description BACKGROUND: Inflammatory myopathies (IMs) are a group of rare conditions characterized by proximal and often symmetrical muscle weakness and reduced muscle endurance. The recommended medical treatment is based on corticosteroids in combination with immunosuppressants. This anti-inflammatory therapy serves to inhibit and prevent inflammation but does not influence impaired muscle strength. Exercise, particularly progressive resistance training, plays therefore an important role in IMs management. Blended therapy, a combination of face-to-face treatment and telerehabilitation, may be a powerful therapy option in improving exercise program adherence in these patients. METHODS: The feasibility of a 12-week interactive tablet-based home exercise program combined with face-to-face therapy sessions – a ‘blended therapy’ approach - was evaluated using a quasi-experimental one-group pre-post comparison design. Primary outcomes were recruitment, attrition and adherence rates, plus measures of acceptance (Technology Acceptance Model Questionnaire (TAM)) and satisfaction (satisfaction questionnaire). Secondary outcomes comprised potential effects of the intervention on muscle strength and function, activity limitation, disability and health-related quality of life. RESULTS: Thirteen of the included 14 participants completed the study without any related adverse events. Mean adherence to exercise program was 84% (range: 25–100%) and participants indicated high acceptance of the intervention with mean TAM scores between 6.1 and 6.5 points. Overall satisfaction with the therapy sessions, the home program, and the technology was good. Approximately half the participants wished for longer training periods and more training sessions per week. There were inconsistent effects on muscle strength, muscle function, activity limitation, disability, and health-related quality of life. CONCLUSION: Blended therapy combining the use of an interactive tablet-based resistance training program with face-to-face therapy sessions is feasible and safe and participants` acceptance with this approach was high. Furthermore, results were obtained that might be useful in selecting appropriate assessments and sample sizes in future trials. TRIAL REGISTRATION: NCT03713151. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40945-021-00108-z.
format Online
Article
Text
id pubmed-8157458
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81574582021-05-28 Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies Pfister, Pierrette Baschung Knols, Ruud H. de Bie, Rob A. de Bruin, Eling D. Arch Physiother Research Article BACKGROUND: Inflammatory myopathies (IMs) are a group of rare conditions characterized by proximal and often symmetrical muscle weakness and reduced muscle endurance. The recommended medical treatment is based on corticosteroids in combination with immunosuppressants. This anti-inflammatory therapy serves to inhibit and prevent inflammation but does not influence impaired muscle strength. Exercise, particularly progressive resistance training, plays therefore an important role in IMs management. Blended therapy, a combination of face-to-face treatment and telerehabilitation, may be a powerful therapy option in improving exercise program adherence in these patients. METHODS: The feasibility of a 12-week interactive tablet-based home exercise program combined with face-to-face therapy sessions – a ‘blended therapy’ approach - was evaluated using a quasi-experimental one-group pre-post comparison design. Primary outcomes were recruitment, attrition and adherence rates, plus measures of acceptance (Technology Acceptance Model Questionnaire (TAM)) and satisfaction (satisfaction questionnaire). Secondary outcomes comprised potential effects of the intervention on muscle strength and function, activity limitation, disability and health-related quality of life. RESULTS: Thirteen of the included 14 participants completed the study without any related adverse events. Mean adherence to exercise program was 84% (range: 25–100%) and participants indicated high acceptance of the intervention with mean TAM scores between 6.1 and 6.5 points. Overall satisfaction with the therapy sessions, the home program, and the technology was good. Approximately half the participants wished for longer training periods and more training sessions per week. There were inconsistent effects on muscle strength, muscle function, activity limitation, disability, and health-related quality of life. CONCLUSION: Blended therapy combining the use of an interactive tablet-based resistance training program with face-to-face therapy sessions is feasible and safe and participants` acceptance with this approach was high. Furthermore, results were obtained that might be useful in selecting appropriate assessments and sample sizes in future trials. TRIAL REGISTRATION: NCT03713151. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40945-021-00108-z. BioMed Central 2021-05-27 /pmc/articles/PMC8157458/ /pubmed/34039438 http://dx.doi.org/10.1186/s40945-021-00108-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Pfister, Pierrette Baschung
Knols, Ruud H.
de Bie, Rob A.
de Bruin, Eling D.
Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies
title Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies
title_full Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies
title_fullStr Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies
title_full_unstemmed Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies
title_short Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies
title_sort feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157458/
https://www.ncbi.nlm.nih.gov/pubmed/34039438
http://dx.doi.org/10.1186/s40945-021-00108-z
work_keys_str_mv AT pfisterpierrettebaschung feasibilityofablendedtherapyapproachinthetreatmentofpatientswithinflammatorymyopathies
AT knolsruudh feasibilityofablendedtherapyapproachinthetreatmentofpatientswithinflammatorymyopathies
AT debieroba feasibilityofablendedtherapyapproachinthetreatmentofpatientswithinflammatorymyopathies
AT debruinelingd feasibilityofablendedtherapyapproachinthetreatmentofpatientswithinflammatorymyopathies